Literature DB >> 23220842

Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.

Andrew X Zhu1, Jennifer J Knox.   

Abstract

Presentation of the Case A 37-year-old woman presented at 35 weeks of gestation with her third child with failure to adequately gain weight and was noted by her obstetrician to have delay in the growth of her baby. Ultrasound of the abdomen incidentally revealed the presence of a liver lesion. After additional evaluation, she ultimately delivered her daughter at 36 weeks uneventfully. She subsequently underwent additional evaluation. Liver magnetic resonance imaging (MRI) revealed a 5-cm solitary solid mass in segment 4A of the liver, concerning for malignancy. Serum α-fetoprotein, carcinoembryonic antigen, cancer antigen (CA)19-9, CA15-3, and CA125 were all normal. Liver biopsy was positive for adenocarcinoma. The tumor cells demonstrated a phenotype suggesting a possible breast primary, although the immunohistochemistry did not support that diagnosis and the tumor was negative for mammaglobin, gross cystic disease fluid protein (GCDFP)-15, estrogen receptor (ER), and progesterone receptor (PR) (Table 1). The tumor was also CDX2 and cardiotrophin-1 negative, but cytokeratin (CK) 19 positive. Her endoscopic retrograde cholangiopancreatography, upper endoscopy, colonoscopy, breast mammogram, and breast MRI were completely normal. A positron emission tomography-computed tomography scan showed a fluorodeoxyglucose-avid 5.8-cm × 6.0-cm hypoattenuating lesion with peripheral enhancement involving segment 4 and segment 8 at the dome. In addition, central necrosis within the lesion was noted. The left main portal vein was mildly attenuated by the mass. She eventually underwent a left hepatectomy en bloc with caudate resection, portal lymphadenectomy, cholecystectomy, and omental pedicle flap. On exploration of the abdomen, no additional disease was noted. The final pathology revealed a 9.4-cm moderately to poorly differentiated adenocarcinoma of the intrahepatic bile ducts. Venous invasion was present. Perineural invasion was absent. The margins were negative. Thirteen lymph nodes were obtained, all of which were negative, consistent with a stage T2, N0, MX intrahepatic cholangiocarcinoma. The tumor was positive for CK7, CK19, and CA19-9 and negative for CK20, CDX2, CA125, ER, PR, GCDFP-15, synaptophysin, and chromogranin (Table 1). The uninvolved liver was unremarkable and a trichrome stain showed no fibrosis. Following an uneventful postoperative recovery, she was referred for consideration of adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23220842      PMCID: PMC3528382          DOI: 10.1634/theoncologist.2012-0432

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  17 in total

Review 1.  Intrahepatic cholangiocarcinoma.

Authors:  George A Poultsides; Andrew X Zhu; Michael A Choti; Timothy M Pawlik
Journal:  Surg Clin North Am       Date:  2010-08       Impact factor: 2.741

Review 2.  Cholangiocarcinoma.

Authors:  Konstantinos N Lazaridis; Gregory J Gores
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

3.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

4.  High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.

Authors:  Russell A Moore; Nelly Adel; Elyn Riedel; Manisha Bhutani; Darren R Feldman; Nour Elise Tabbara; Gerald Soff; Rekha Parameswaran; Hani Hassoun
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

5.  Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.

Authors:  Mechteld C de Jong; Hari Nathan; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; T Clark Gamblin; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Richard D Schulick; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

Review 6.  Risk factors for cholangiocarcinoma.

Authors:  Gia L Tyson; Hashem B El-Serag
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

Review 7.  Recent advances in the management of cholangiocarcinomas.

Authors:  J N Vauthey; L H Blumgart
Journal:  Semin Liver Dis       Date:  1994-05       Impact factor: 6.115

8.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

9.  Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.

Authors:  Itaru Endo; Mithat Gonen; Adam C Yopp; Kimberly M Dalal; Qin Zhou; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Yuman Fong; Lawrence Schwartz; Nancy Kemeny; Eileen O'Reilly; Ghassan K Abou-Alfa; Hiroshi Shimada; Leslie H Blumgart; William R Jarnagin
Journal:  Ann Surg       Date:  2008-07       Impact factor: 12.969

10.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

Authors:  Yasser H Shaib; Jessica A Davila; Kathryn McGlynn; Hashem B El-Serag
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

View more
  11 in total

Review 1.  Surgical options for intrahepatic cholangiocarcinoma.

Authors:  Kui Wang; Han Zhang; Yong Xia; Jian Liu; Feng Shen
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 2.  Epidemiology and surgical management of intrahepatic cholangiocarcinoma.

Authors:  Han Zhang; Feng Shen; Jun Han; Yi-Nan Shen; Guo-Qiang Xie; Meng-Chao Wu; Tian Yang
Journal:  Hepat Oncol       Date:  2015-11-30

Review 3.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

4.  Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models.

Authors:  Alexandre Doussot; Bas Groot-Koerkamp; Jimme K Wiggers; Joanne Chou; Mithat Gonen; Ronald P DeMatteo; Peter J Allen; T Peter Kingham; Michael I D'Angelica; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2015-04-24       Impact factor: 6.113

Review 5.  Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.

Authors:  Yun-Feng Wang; Fei-Ling Feng; Xu-Hong Zhao; Zhen-Xiong Ye; He-Ping Zeng; Zhen Li; Xiao-Qing Jiang; Zhi-Hai Peng
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

6.  The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection.

Authors:  Young Saing Kim; Chi-Young Jeong; Haa-Na Song; Tae Hyo Kim; Hong Jun Kim; Young-Joon Lee; Soon Chan Hong
Journal:  Chin J Cancer       Date:  2017-01-13

Review 7.  Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma.

Authors:  Pavan Najran; Angela Lamarca; Damian Mullan; Mairéad G McNamara; Thomas Westwood; Richard A Hubner; Jeremy Lawrence; Prakash Manoharan; Jon Bell; Juan W Valle
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

8.  In the literature: June 2019.

Authors:  Angela Lamarca; Valentina Gambardella; Juan-Miguel Cejalvo; Tania Fleitas-Kanonnikoff; Andrés Cervantes
Journal:  ESMO Open       Date:  2019-06-20

9.  Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma.

Authors:  Stefan Buettner; David W G Ten Cate; Fabio Bagante; Sorin Alexandrescu; Hugo P Marques; Jorge Lamelas; Luca Aldrighetti; T Clark Gamblin; Shishir K Maithel; Carlo Pulitano; Georgios Antonios Margonis; Matthew Weiss; Todd W Bauer; Feng Shen; George A Poultsides; J Wallis Marsh; Jan N M IJzermans; Timothy M Pawlik; Bas Groot Koerkamp
Journal:  J Gastrointest Surg       Date:  2019-03-18       Impact factor: 3.452

10.  Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis.

Authors:  Ka Wing Ma; Tan To Cheung; Brian Leung; Brian Wong Hoi She; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Wing Chiu Dai; Chung Mau Lo
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.